VRTX241004C477500
- 0.70
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Capricor Stock Rallies 20% on DMD Data Presentation Update
National Bank on DRI Healthcare's Casgevy Stream Acquisition
Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $425
Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Vertex Pharmaceuticals (VRTX) and Edwards Lifesciences (EW)
DBS Initiates Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Avidity Gets FDA Partial Clinical Hold Lifted on DM1 Drug Candidate
Reasons That Lifted Vertex Pharmaceuticals Incorporated (VRTX) in Q2
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Raises Target Price to $502
Wolfe Research Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $518
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $518 From $576, Maintains Outperform Rating
What Analysts Are Saying About Vertex Pharmaceuticals Stock
Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Raises Target Price to $474
Express News | Vertex Pharmaceuticals Inc : Morgan Stanley Raises Target Price to $474 From $462
Maintaining Hold Rating on Vertex Pharmaceuticals Amidst LSR Trial Uncertainties
Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $515
Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Presents Vanzacaftor/tezacaftor/deutivacaftor Data